Evidence map›Paper›PMID 33541278›Full record

ArticleBMC infectious diseases2021

Factors associated with delayed presentation to healthcare facilities for Lassa fever cases, Nigeria 2019: a retrospective cohort study.

Nastassya L Chandra, Hikaru Bolt, Chioma Dan-Nwafor, Oladipupo Ipadeola, Elsie Ilori, Geoffrey Namara, Adebola T Olayinka, Winifred Ukponu, Akanimo Iniobong, Michael Amedu and 10 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 3 countries.

Nastassya L ChandraUK Field Epidemiology Training Programme, Public Health England, London, UK. Nastassya.chandra@phe.gov.uk.ORCID http://orcid.org/0000-0002-6259-230X
Hikaru BoltUK Public Health Rapid Support Team - Public Health England/London School of Hygiene & Tropical Medicine, London, UK.
Chioma Dan-NwaforNigeria Centre for Disease Control, Abuja, Nigeria.
Oladipupo IpadeolaNigeria Centre for Disease Control, Abuja, Nigeria.
Elsie IloriNigeria Centre for Disease Control, Abuja, Nigeria.
Geoffrey NamaraNigeria Centre for Disease Control, Abuja, Nigeria.
Adebola T OlayinkaNigeria Centre for Disease Control, Abuja, Nigeria.
Winifred UkponuGeorgetown University, Centre for Global Health Practice and Impact, Abuja, Nigeria.
Akanimo IniobongNigeria Centre for Disease Control, Abuja, Nigeria.
Michael AmeduNigeria Centre for Disease Control, Abuja, Nigeria.
Adejoke AkanoNigeria Centre for Disease Control, Abuja, Nigeria.
Kachikwulu O AkabikeNigeria Centre for Disease Control, Abuja, Nigeria.
Uwaifiokun OkhuaroboEdo State Ministry of Health, Edo, Nigeria.
Stephen FagbemiOndo State Ministry of Health, Ondo, Nigeria.
Emeka SampsonEbonyi State Ministry of Health, Ebonyi, Nigeria.
Sophie NewittPublic Health England, National Infection Service, London, UK.
Neville Q VerlanderPublic Health England, National Infection Service, London, UK.
Daniel G BauschUK Public Health Rapid Support Team - Public Health England/London School of Hygiene & Tropical Medicine, London, UK.
Olivier le Polain de WarouxUK Public Health Rapid Support Team - Public Health England/London School of Hygiene & Tropical Medicine, London, UK.
Chikwe IhekweazuNigeria Centre for Disease Control, Abuja, Nigeria.
Nigeria Centre for Disease Control · NGPublic Health England · GBWorld Health Organization - Nigeria · NGEbonyi State University · NGGeorgetown University · USOlusegun Agagu University of Science and Technology · NG

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundLarge outbreaks of Lassa fever (LF) occur annually in Nigeria. The case fatality rate among hospitalised cases is ~ 20%. The antiviral drug ribavirin along with supportive care and rehydration are the recommended treatments but must be administered early (within 6 days of symptom onset) for optimal results. We aimed to identify factors associated with late presentation of LF cases to a healthcare facility to inform interventions.

methodsWe undertook a retrospective cohort study of all laboratory confirmed LF cases reported in Nigeria from December 2018 to April 2019. We performed descriptive epidemiology and a univariate Cox proportional-hazards regression analysis to investigate the effect of clinical (symptom severity), epidemiological (age, sex, education, occupation, residential State) and exposure (travel, attendance at funeral, exposure to rodents or confirmed case) factors on time to presentation.

resultsOf 389 cases, median presentation time was 6 days (IQR 4-10 days), with 53% attending within 6 days. There were no differences in presentation times by sex but differences were noted by age-group; 60+ year-olds had the longest delays while 13-17 year-olds had the shortest. By sex and age, there were differences seen among the younger ages, with 0-4-year-old females presenting earlier than males (4 days and 73% vs. 10 days and 30%). For 5-12 and 13-17 year-olds, males presented sooner than females (males: 5 days, 65% and 3 days, 85% vs. females: 6 days, 50% and 5 days, 61%, respectively). Presentation times differed across occupations 4.5-9 days and 20-60%, transporters (people who drive informal public transport vehicles) had the longest delays. Other data were limited (41-95% missing). However, the Cox regression showed no factors were statistically associated with longer presentation time.

conclusionsWhilst we observed important differences in presentation delays across factors, our sample size was insufficient to show any statistically significant differences that might exist. However, almost half of cases presented after 6 days of onset, highlighting the need for more accurate and complete surveillance data to determine if there is a systemic or specific cause for delays, so to inform, monitor and evaluate public health strategies and improve outcomes.

Indexed as

Time-to-TreatmentAdolescentAdultAntiviral AgentsChildChild, PreschoolCohort StudiesFemaleHumansInfantLassa FeverMaleMiddle AgedNigeriaProportional Hazards ModelsRetrospective StudiesAntiviral AgentsRibavirinDelayed presentationEpidemiologyHealthcareLassa feverNigeriaRetrospective cohort studySurveillance

Identifiers

PMID33541278
PMCPMC7863257
OpenAlexW3126340336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.